HLUBF (H. Lundbeck AS) Total Equity: $3,964 Mil (As of Mar. 2026)


HLUBF H. Lundbeck AS HLUBF
78 GF Score
Price $5.50
GF Value $5.65
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is H. Lundbeck AS Total Equity?

H. Lundbeck AS HLUBF 78 Total Equity is $3,964 Mil as of Mar. 2026. GuruFocus rates HLUBF with a GF Score™ of 78/100 and a GF Value™ of $5.65 (Fairly Valued). The stock has 3 warning signs investors should review.

H. Lundbeck AS's total equity for the quarter that ended in Mar. 2026 was $3,964 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

H. Lundbeck AS Total Equity Historical Data

* Premium members only.

The historical data trend for H. Lundbeck AS's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

H. Lundbeck AS Total Equity Chart

H. Lundbeck AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,777.54 2,958.75 3,225.41 3,511.61 3,904.27

H. Lundbeck AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,561.38 3,739.95 3,955.50 3,904.27 3,963.62
HLUBF
78GF Score
H. Lundbeck AS HLUBF
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

H. Lundbeck AS Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

H. Lundbeck AS's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=8160.981-4256.71
=3,904

H. Lundbeck AS's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=8090.112-4126.491
=3,964

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $3,964 Mil mean?
H. Lundbeck AS (HLUBF) has a Total Equity of $3,964 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for H. Lundbeck AS and its competitors.
Is H. Lundbeck AS's Total Equity too high?
H. Lundbeck AS's current Total Equity is $3,964 Mil. Overall, H. Lundbeck AS has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does H. Lundbeck AS's Total Equity compare to ZTS and UTHR?
H. Lundbeck AS's Total Equity of $3,964 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for H. Lundbeck AS and its competitors. H. Lundbeck AS's current Total Equity is $3,964 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is H. Lundbeck AS stock overvalued right now?
Based on GuruFocus' analysis, H. Lundbeck AS (HLUBF) is currently considered Fairly Valued. The stock's GF Value™ is $5.65, compared to a current price of $5.50 — trading 2.7% below its estimated fair value. The current Total Equity is $3,964 Mil. H. Lundbeck AS's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For H. Lundbeck AS (HLUBF), the current Total Equity is $3,964 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is H. Lundbeck AS (HLUBF) Overvalued in 2026?

Based on GuruFocus' analysis, H. Lundbeck AS stock appears to be undervalued. The current stock price of $5.50 is trading 2.7% below its estimated GF Value™ of $5.65. GuruFocus considers H. Lundbeck AS to be Fairly Valued.

Key valuation signals for HLUBF:

  • Total Equity: $3,964 Mil
  • GF Value™: $5.65 vs. price of $5.50 (2.7% below fair value)
  • GF Score™: 78/100 with 3 warning signs

No single metric tells the full story. See the HLUBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

H. Lundbeck AS Business Description

Address Ottiliavej 9, Valby, DNK, 2500
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
78GF Score

Get the complete analysis for HLUBF

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.50
Price
$5.65
GF Value